Our innovation pipeline
Our innovation programs
In order to provide technologies that answer current unmet needs in oral formulation, Skyepharma launched an Innovation pipeline. Our research programs in collaboration with international universities and research institutes address issues such as bioavailability, precision delivery and long extended release. Here are some of our pharmaceutical innovation programs :
GeoBiologicS Program
This program was introduced by Skyepharma to enhance treatment solutions based on biologics.
Biologics (proteins, peptides, and therapeutic antibodies) have been successfully developed for the treatment of illnesses such as diabetes, metabolic diseases, rheumatoid arthritis, inflammatory bowel disease, and cancer. Although the oral administration of these biomolecules has shown promise, most available treatments are predominantly intravenous, and oral formulations have yet to be extensively explored in clinical settings.
Skyepharma is collaborating with the University of Bordeaux to develop a unique formulation platform derived from its patented Geoclock® technology (Tab-In-Tab), which enables local or systemic delivery of biologics.
Skyepharma is open to partnerships with pharmaceutical and biotech companies involved in the development of biomolecules. Please contact us to learn more.
NanoMicS & NanoFact
Most new chemical entities shows low solubility in biological fluids (Class II and IV molecules according to the Biopharmaceutics Classification System), leading to poor bioavailability.
Skyepharma is collaborating with the University of Lyon on the development of tablet formulations containing nanoparticles, aimed at reducing food effects and metabolism while increasing drug delivery to the pharmacological site (local or systemic) for BCS II/IV molecules. The process, based on high-pressure homogenization, is solvent-free and fully scalable. Skyepharma has also joined the Nanofact consortium to develop continuous manufacturing equipment for nanoparticles.
We are open to partnerships with pharmaceutical and biotech companies addressing bioavailability challenges.
GeoColon program
Colon-targeting is of particular interest for reducing off-target side effects and increasing local delivery of the active drug for inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. It is also a promising approach for emerging therapeutic targets, including the microbiome, enteric immune system, and lymphatic system.
Skyepharma is collaborating with the University of Lille to develop a formulation that enables the release of the active ingredient in the presence of colonic bacteria.
We are open to partnerships with pharmaceutical and biotech companies targeting colon-located therapeutic sites.
MucoTabS program
The precise delivery and long-lasting release is essential to optimize the efficacy of oral treatments.
The MucoTabS innovation program, in collaboration with the University of Lyon, aims to develop a technology platform capable of targeting different regions of the gastrointestinal (GI) tract (stomach, small intestine, colon) while promoting muco-adhesion to increase the local residence time of the active pharmaceutical ingredient (API). This approach enables the local or systemic release of the API over a period of 24 hours or more, potentially reducing dosage strength and minimizing side effects.
We are open to partnerships with pharmaceutical and biotech companies seeking extended-release solutions for their active ingredients.
Soctec®: Extended Release Gastro-retentive Platform Technology
Our innovation team
– Nivetha UTHAYAKUMAR –
Pharmacist specialized in Pharmacotechnics (University of Paris) and holding a Master’s degree in Industrial Pharmaceutical Formulation (University of Lille).
GeoBiologicS project
– Oksana LEMASSON –
PhD pharmacist from the University of Lyon (ISPB) and holding a Master’s in “Industrial Cosmetology” from the Lyon Institute of Industrial Pharmacy
She is studing how lipid nanoparticles could be used to enhance the oral bioavailability of poorly soluble and poorly permeable active ingredients
– Pauline TARLET –
PhD student at Claude Bernard University Lyon 1, previously earned a master’s degree from the High School of Chemistry and Electronics in Lyon.
MucoTabS project
